【摘 要】
:
ObjectiveLung cancer cells associated with radioresistance are likely to give rise to local recurrence and distant metastatic relapse, but little is known about its underlying mechanisms. In the prese
【机 构】
:
TianjinKeyLaboratoryofRadiationMedicineandMolecularNuclearMedicine,InstituteofRadiationMedicine,Chin
论文部分内容阅读
ObjectiveLung cancer cells associated with radioresistance are likely to give rise to local recurrence and distant metastatic relapse, but little is known about its underlying mechanisms. In the present paper, the effects of the HPV16 E6 and HPV16 E7 oncoprotein on the radiosensitivity of lung cancer cell lines were investigated.
MethodsThe HPV16 E6 or HPV16 E7 oncoprotein was expressed by a transient transfection with pcDNA3-HPV16 E6 or pcDNA3-HPV16 E7 expression vector. Human lung cancer H2179 cells and mouse lung cancer Lewis cells were exposed to a γ-ray radiation source, cellular survival was evaluated by using a colony formation assay. The expression of HPV16 oncoproteins E6/E7, extracellular signal-regulated kinases 1/2(ERK1/2) and AKT signaling was determined by Western blot assay. VEGF secretion was determined by ELISA.
ResultsBoth HPV16 oncoproteins E6 and E7 significantly decreased radiosensitivity of H2179 cells, associated with a promotion of the ERK1/2 and AKT phosphorylation. A decrease of reactive oxygen species(ROS) and an increase of VEGF levels were observed in the cells expressing the HPV16 oncoproteins E6 and E7. Furthermore, a similar reduction of radiosensitivity mediated by the HPV16 oncoproteins E6 and E7 was also observed in a mouse lung cancer Lewis cells.
ConclusionThe findings indicate that the HPV16 oncoproteins E6 and E7 negatively affects susceptibility of lung cancer cells to radiotherapy via regulation of the ERK1/2 and Akt signaling pathway and VEGF expression.
其他文献
Long non-coding RNAs(lncRNAs) are increasingly involved in diverse biological processes. Upon DNA damage, the DNA damage response(DDR) elicits a complex signaling cascade, which includes the induction
测定肿瘤细胞凋亡是早期评价肿瘤疗效的指标之一,放射性核素凋亡显像是目前研究最为广泛、技术最为成熟的体内肿瘤细胞凋亡分子影像学检测技术,能在活体内动态、无创地检测抗肿瘤治疗引起的细胞凋亡,有助于肿瘤疗效的早期评判和预后分析,其中特异性分子探针技术的研究开发是放射性核素凋亡显像的关键技术之一。笔者将目前有代表性的肿瘤细胞凋亡核素显像分子探针进行了总结。
目的用国产11C-多功能合成模块经LOOP环法合成放射性药物11C-蛋氨酸(11C-MET),与C-18柱固相法合成11C-蛋氨酸进行比较。方法对国产模块LOOP环法制备11C-MET的合成工艺进行探讨,研究碱当量、溶剂效应及前体量等影响因素。结果LOOP环法制备11C-MET优化后的合成条件:前体量2~3 mg溶于NaOH溶液(2 mol/L),碱当量5.6~11.5 eq,加入乙醇100 μl
ObjectiveA nucleosomal protein, HMGB1, can be secreted by activated immune cells or passively released by dying cells, thereby amplifying rigorous inflammatory responses. In this study we aimed to tes
目的评价广泛期小细胞肺癌(SCLC)化疗后接受胸部IMRT,发生放射性肺炎(RP)的临床和剂量-体积因素。方法回顾性分析2007年至2012年接受化疗和IMRT的130例初治广泛期SCLC患者,化疗方案以顺铂、依托泊甙方案为主,放疗平均剂量为55.3 Gy(32~67 Gy)。RP采用常见不良反应事件评价标准(4.0版)进行评价,分析放疗结束后2级及以上RP发生的危险因素。通过单因素和多因素统计学
Biomarkers, such as chromosome aberration and micronuclei assays, prove to be reliable for facilitating clinical diagnosis in radiation accidents. In a radiation accident in India, chromosomal aberrat
乳腺癌是全球女性发病率最高的恶性肿瘤,为保证患者的生存率、减少术后并发症,20世纪90年代用 "腋窝前哨淋巴结活检术取代腋窝淋巴结清扫" 的观点被提出并逐渐发展成为乳腺癌患者保乳术的常规方法。除腋窝前哨淋巴结外,内乳前哨淋巴结的重要性同样不容忽视,但是否将其作为前哨淋巴结活检的对象仍存在争议。面对目前形势,核医学工作者做了大量研究,在保证腋窝前哨淋巴结高显示率的同时尽可能提高内乳前哨淋巴结的显示率
miRNA是一类非编码的小RNA,它主要利用碱基互补配对的方式与特异性靶基因信使RNA的3'-非翻译区结合,通过降解靶RNA或抑制蛋白质的翻译合成,从而实现对靶基因转录后水平的调控。放射治疗是治疗肿瘤的主要手段之一,肿瘤的辐射生物效应对其放疗效果至关重要,也是确定某肿瘤组织辐射敏感或辐射耐受的一个重要因素。研究证实,miRNAs通过影响DNA损伤修复、细胞周期检查点、凋亡、信号转导、肿瘤组织微环境
目的比较99Tcm-MIBI SPECT/CT显像和钼靶X线对女性乳腺癌的诊断价值。方法女性患者83例,先行99Tcm-MIBI胸部SPECT/CT早期显像和延迟显像,并以延迟显像阳性为判定标准,再行乳腺钼靶X线摄影,并与最终的病理结果进行对照。结果延迟显像的阳性患者为52例(T/NT值>3.33),阳性与阴性病灶的早期、延迟显像分别比较,差异均有统计学意义,且以延时2 h结果更为显著,最终病理结
目的基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤(HL)复发诊断中的应用价值。方法基于Deauville标准,回顾性分析24例治疗结束后5~27个月,临床可疑复发的HL患者,对其18F-FDG PET/CT显像结果进行评分判断,并与淋巴结活检和(或)骨髓活检病理结果进行对照分析。结果病理结果证实17例复发、3例淋巴结反应性增生、1例肺癌并纵隔淋巴结转移、3例未见明确复发